BRIEF-Pfizer Says Drug Pricing Agreement With US Government Has No Impact On 2025 Guidance

Reuters

Nov 04, 2025

BRIEF-Pfizer Says Drug Pricing Agreement With US Government Has No Impact On 2025 Guidance

Nov 4 (Reuters) - Pfizer:

PFIZER CEO SAYS "OUR BELIEF IN THE PROMISE OF THE PFIZER AND METSERA COMBINATION IS STRONG AND UNWAVERING" - PREPARED REMARKS
PFIZER: PLANNING TO START PHASE 3 FOR ADULT 25-VALENT PROGRAM STUDY NEXT YEAR, IF FDA ALIGNS WITH OUR APPROACH - PREPARED REMARKS
PFIZER: FOR ABRYSVO, IN U.S., EXPERIENCING HEADWIND OF MORE DIFFICULT TO ACTIVATE POPULATION AS WE ENTER THIRD SEASON OF RSV - PREPARED REMARKS
PFIZER CFO: GOING FORWARD, COST MANAGEMENT ACROSS OUR MANUFACTURING NETWORK REMAINS A TOP PRIORITY - PREPARED REMARKS
PFIZER: DRUG PRICING AGREEMENT WITH US GOVERNMENT HAS NO IMPACT ON 2025 GUIDANCE, EXPECT DILUTIVE IMPACT TO 2026 FINANCIAL OUTLOOK - PREPARED REMARKS
PFIZER: THERE IS SOFTNESS IN OUR COVID PRODUCTS DUE TO LOWER VACCINATION RATES AND COVID INFECTION RATES - PREPARED REMARKS
PFIZER: NOW EXPECT 2025 ADJUSTED RESEARCH AND DEVELOPMENT TO BE IN THE RANGE OF $10.0 BILLION TO $11.0 BILLION - PREPARED REMARKS

Further company coverage: PFE.N

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580755589"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580755589\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580755589?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 22:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580755589","market":"nz","top_or_hot":-1,"title":"BRIEF-Pfizer Says Drug Pricing Agreement With US Government Has No Impact On 2025 Guidance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pfizer Says Drug Pricing Agreement With US Government Has No Impact On 2025 Guidance</title></head><body><p><span>Nov 4 (Reuters)</span><span> - </span>Pfizer:</p><ul><li><p>PFIZER CEO SAYS \"OUR BELIEF IN THE PROMISE OF THE PFIZER AND METSERA COMBINATION IS STRONG AND UNWAVERING\" - PREPARED REMARKS</p></li><li><p>PFIZER:  PLANNING TO START PHASE 3 FOR ADULT 25-VALENT PROGRAM STUDY NEXT YEAR, IF FDA ALIGNS WITH OUR APPROACH - PREPARED REMARKS</p></li><li><p>PFIZER: FOR ABRYSVO, IN U.S., EXPERIENCING HEADWIND OF MORE DIFFICULT TO ACTIVATE POPULATION AS WE ENTER THIRD SEASON OF RSV - PREPARED REMARKS</p></li><li><p>PFIZER CFO: GOING FORWARD, COST MANAGEMENT ACROSS OUR MANUFACTURING NETWORK REMAINS A TOP PRIORITY - PREPARED REMARKS</p></li><li><p>PFIZER: DRUG PRICING AGREEMENT WITH US GOVERNMENT HAS NO IMPACT ON 2025 GUIDANCE, EXPECT DILUTIVE IMPACT TO 2026 FINANCIAL OUTLOOK - PREPARED REMARKS</p></li><li><p>PFIZER: THERE IS SOFTNESS IN OUR COVID PRODUCTS DUE TO LOWER VACCINATION RATES AND COVID INFECTION RATES - PREPARED REMARKS</p></li><li><p>PFIZER: NOW EXPECT 2025 ADJUSTED RESEARCH AND DEVELOPMENT TO BE IN THE RANGE OF $10.0 BILLION TO $11.0 BILLION - PREPARED REMARKS</p></li></ul><p>Further company coverage: <span>PFE.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Pfizer Says Drug Pricing Agreement With US Government Has No Impact On 2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Pfizer Says Drug Pricing Agreement With US Government Has No Impact On 2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 22:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pfizer Says Drug Pricing Agreement With US Government Has No Impact On 2025 Guidance</title></head><body><p><span>Nov 4 (Reuters)</span><span> - </span>Pfizer:</p><ul><li><p>PFIZER CEO SAYS \"OUR BELIEF IN THE PROMISE OF THE PFIZER AND METSERA COMBINATION IS STRONG AND UNWAVERING\" - PREPARED REMARKS</p></li><li><p>PFIZER:  PLANNING TO START PHASE 3 FOR ADULT 25-VALENT PROGRAM STUDY NEXT YEAR, IF FDA ALIGNS WITH OUR APPROACH - PREPARED REMARKS</p></li><li><p>PFIZER: FOR ABRYSVO, IN U.S., EXPERIENCING HEADWIND OF MORE DIFFICULT TO ACTIVATE POPULATION AS WE ENTER THIRD SEASON OF RSV - PREPARED REMARKS</p></li><li><p>PFIZER CFO: GOING FORWARD, COST MANAGEMENT ACROSS OUR MANUFACTURING NETWORK REMAINS A TOP PRIORITY - PREPARED REMARKS</p></li><li><p>PFIZER: DRUG PRICING AGREEMENT WITH US GOVERNMENT HAS NO IMPACT ON 2025 GUIDANCE, EXPECT DILUTIVE IMPACT TO 2026 FINANCIAL OUTLOOK - PREPARED REMARKS</p></li><li><p>PFIZER: THERE IS SOFTNESS IN OUR COVID PRODUCTS DUE TO LOWER VACCINATION RATES AND COVID INFECTION RATES - PREPARED REMARKS</p></li><li><p>PFIZER: NOW EXPECT 2025 ADJUSTED RESEARCH AND DEVELOPMENT TO BE IN THE RANGE OF $10.0 BILLION TO $11.0 BILLION - PREPARED REMARKS</p></li></ul><p>Further company coverage: <span>PFE.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL8N3WG24O:1","article_id":"2580755589","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580755589","pubTimestamp":1762267809,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Pfizer Says Drug Pricing Agreement With US Government Has No Impact On 2025 GuidanceNov 4  - Pfizer:PFIZER CEO SAYS \"OUR BELIEF IN THE PROMISE OF THE PFIZER AND METSERA COMBINATION IS STRONG AND UNWAVERING\" - PREPARED REMARKSPFIZER:  PLANNING TO START PHASE 3 FOR ADULT 25-VALENT PROGRAM STUDY NEXT YEAR, IF FDA ALIGNS WITH OUR APPROACH - PREPARED REMARKSPFIZER: FOR ABRYSVO, IN U.S., EXPERIENCING HEADWIND OF MORE DIFFICULT TO ACTIVATE POPULATION AS WE ENTER THIRD SEASON OF RSV - PREPARED REMARKSPFIZER CFO: GOING FORWARD, COST MANAGEMENT ACROSS OUR MANUFACTURING NETWORK REMAINS A TOP PRIORITY - PREPARED REMARKSPFIZER: DRUG PRICING AGREEMENT WITH US GOVERNMENT HAS NO IMPACT ON 2025 GUIDANCE, EXPECT DILUTIVE IMPACT TO 2026 FINANCIAL OUTLOOK - PREPARED REMARKSPFIZER: THERE IS SOFTNESS IN OUR COVID PRODUCTS DUE TO LOWER VACCINATION RATES AND COVID INFECTION RATES - PREPARED REMARKSPFIZER: NOW EXPECT 2025 ADJUSTED RESEARCH AND DEVELOPMENT TO BE IN THE RANGE OF $10.0 BILLION TO $11.0 BILL","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4599":"减肥药","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4585":"ETF&股票定投概念","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4139":"生物科技","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0058720904.USD":"联博国际健康护理基金A","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","MTSR":"Metsera Inc.","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4592":"伊斯兰概念","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","PFE":"辉瑞","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4568":"美国抗疫概念","BK4588":"碎股","BK4550":"红杉资本持仓","SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BK4007":"制药","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD"},"translate_title":"简报-辉瑞表示与美国政府的药品定价协议对2025年指导没有影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":0.9,"MTSR":0.9},"content_text":"BRIEF-Pfizer Says Drug Pricing Agreement With US Government Has No Impact On 2025 GuidanceNov 4 (Reuters) - Pfizer:PFIZER CEO SAYS \"OUR BELIEF IN THE PROMISE OF THE PFIZER AND METSERA COMBINATION IS STRONG AND UNWAVERING\" - PREPARED REMARKSPFIZER:  PLANNING TO START PHASE 3 FOR ADULT 25-VALENT PROGRAM STUDY NEXT YEAR, IF FDA ALIGNS WITH OUR APPROACH - PREPARED REMARKSPFIZER: FOR ABRYSVO, IN U.S., EXPERIENCING HEADWIND OF MORE DIFFICULT TO ACTIVATE POPULATION AS WE ENTER THIRD SEASON OF RSV - PREPARED REMARKSPFIZER CFO: GOING FORWARD, COST MANAGEMENT ACROSS OUR MANUFACTURING NETWORK REMAINS A TOP PRIORITY - PREPARED REMARKSPFIZER: DRUG PRICING AGREEMENT WITH US GOVERNMENT HAS NO IMPACT ON 2025 GUIDANCE, EXPECT DILUTIVE IMPACT TO 2026 FINANCIAL OUTLOOK - PREPARED REMARKSPFIZER: THERE IS SOFTNESS IN OUR COVID PRODUCTS DUE TO LOWER VACCINATION RATES AND COVID INFECTION RATES - PREPARED REMARKSPFIZER: NOW EXPECT 2025 ADJUSTED RESEARCH AND DEVELOPMENT TO BE IN THE RANGE OF $10.0 BILLION TO $11.0 BILLION - PREPARED REMARKSFurther company coverage: PFE.N ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}